Zobrazeno 171 - 176
of 176
pro vyhledávání: '"Chafika Mazouni"'
Autor:
A. M. Gonzalez-Angulo, Lajos Pusztai, Funda Meric-Bernstam, Chafika Mazouni, Florentia Peintinger, Fabrice Andre, Gabriel N. Hortobagyi, V. Valero, S. Wan-Kau, Fraser Symmans
Publikováno v:
Journal of Clinical Oncology. 25:530-530
530 Background: To determine whether residual ductal carcinoma in situ (DCIS) after completion of preoperative chemotherapy affects the outcome of patients with hiostologically defined complete eradication of invasive cancer. Methods: Retrospective a
Autor:
Gabriel N. Hortobagyi, Marjorie C. Green, Cornelia Liedtke, S. W. Kau, William Fraser Symmans, A. M. Gonzalez-Angulo, Debra Frye, Fabrice Andre, Lajos Pusztai, Chafika Mazouni
Publikováno v:
Journal of Clinical Oncology. 25:548-548
548 Purpose: We examined the correlation between HER2 expression and pathologic complete response (pCR) to paclitaxel/FAC (T/FAC) preoperative chemotherapy in stage II-III breast cancer. Patients and Methods: Retrospective analysis of data including
Autor:
William Fraser Symmans, Fabrice Andre, Chafika Mazouni, Gabriel N. Hortobagyi, Attila Tordai, Cornelia Liedtke, Marjorie C. Green, Kenneth R. Hess, Lajos Pusztai, A. M. Gonzalez-Angulo
Publikováno v:
Journal of Clinical Oncology. 25:10519-10519
10519 Objective. Triple-negative breast cancer is defined as a subtype of invasive breast cancer which lacks estrogen and progesterone receptor expression as well as HER2/neu expression and is highly similar to the basal-like subtype defined by gene
Autor:
Chafika Mazouni, Angeline Hall, Kristine Broglio, Herbert Fritsche, Fabrice Andre, Francisco J. Esteva, Gabriel N. Hortobagyi, Aman U. Buzdar, Lajos Pusztai, Massimo Cristofanilli
Publikováno v:
Cancer (0008543X); Feb2007, Vol. 109 Issue 3, p496-501, 6p
Publikováno v:
Journal of Endourology; Nov2004, Vol. 18 Issue 9, p901-905, 5p
Autor:
M-C Mathieu, K. Hofert, R. Rahhali, Z. Fadoukhair, D. Lefeuvre, Emilie Lanoy, Chafika Mazouni, Suzette Delaloge
Publikováno v:
ResearcherID
Emilie Lanoy
Emilie Lanoy
Background WHO classification has identified a dozen rare subtypes that account for less than 10% of all breast cancers (BC). They are generally not taken into account in international/national treatment (trt) guidelines. We evaluated professionals'
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d0f66d0a3eeea0c05747c1e7a96f8b6
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000309409000291&KeyUID=WOS:000309409000291
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000309409000291&KeyUID=WOS:000309409000291